CDC Logo Skip Top Nav
 CDC Home PageSearch the CDCHealth Topics A though Z
Skip
Division of Tuberculosis Elimination
About DTBE Upcoming Events Site Map CDC en Espanol Contact Us
 

Treatment of Tuberculosis (2003)

Return to Slide Sets Main Menu

This slide set was developed as an accompaniment to Treatment of Tuberculosis, a joint statement by CDC, the American Thoracic Society, and the Infectious Diseases Society of America. The slide set provides an overview of the current recommendations for the treatment of tuberculosis.

Download complete set (65 slides) in PowerPoint format - (581 KB)

NOTE: To download images to your local drive, right click on the image with your mouse, and choose "Save Picture As". In the pop up menu that follows, navigate to a location where you would like to place the file, and click "Save."  To enlarge an image, or to navigate the presentation on the web, click on any image.

The slide set is in the public domain. You may reproduce these slides without permission. You are also free to adapt and revise these slides; however, you must remove the CDC name and logo if changes are made.

Slide 1: Treatment of Tuberculosis. Click here for larger image
d
Slide 2: Why a New TB Treatment Statement? Click here for larger image
d
Slide #1 Slide #2
Slide 3: What's New? (1). Click here for larger image
d
Slide 4: What's New? (2). Click here for larger image
d
Slide #3 Slide #4
Slide 5: What's New? (3). Click here for larger image
d
Slide 6: What's New? (4). Click here for larger image
d
Slide #5 Slide #6
Slide 7: Fundamental Responsibility and Approach in TB Treatment. Click here for larger image
d
Slide 8: Antituberculosis Drugs. Click here for larger image
d
Slide #7 Slide #8
Slide 9: Drug Abbreviations. Click here for larger image
d
Slide 10: Role of New Drugs (1). Click here for larger image
d
Slide #9 Slide #10
Slide 11: Role of New Drugs (2). Click here for larger image
d
Slide 12: Factors Guiding Treatment Initiation. Click here for larger image
d
Slide #11 Slide #12
Slide 13: When to Consider Treatment Initiation. Click here for larger image
d
Slide 14: Baseline Diagnostic Examinations for TB. Click here for larger image
d
Slide #13 Slide #14
Slide 15: Other Examinations to Conduct When TB Treatment is Initiated (1). Click here for larger image
d
Slide 16: Other Examinations to Conduct When TB Treatment is Initiated (2). Click here for larger image
d
Slide #15 Slide #16
Slide 17: IDSA/USPHS* Rating System for Treatment Recommendations. Click here for larger image
d
Slide 18: Treatment Regimens. Click here for larger image
d
Slide #17 Slide #18
Slide 19: Why Extend Continuation-Phase Treatment for 3 Months? Click here for larger image
d
Slide 20: When to Extend Continuation-Phase Treatment for 3 Months? Click here for larger image
d
Slide #19 Slide #20
Slide 21: Algorithm to Guide Duration of Continuation-Phase Treatment 
          for Culture-Positive TB Patients. Click here for larger image
d
Slide 22: Algorithm to Guide Duration of Continuation-Phase Treatment 
          for Culture-Positive TB Patients (continued). Click here for larger image
d
Slide #21 Slide #22
Slide 23: Treatment of Culture-Positive TB (1). Click here for larger image
d
Slide 24: Treatment of Culture-Positive TB (2). Click here for larger image
d
Slide #23 Slide #24
Slide 25: Treatment of Culture-Positive TB (3). Click here for larger image
d
Slide 26: Treatment of Culture-Positive TB (4). Click here for larger image
d
Slide #25 Slide #26
Slide 27: Algorithm to Guide Rifapentine (RPT) Use in the Continuation Phase. Click here for larger image
d
Slide 28: Algorithm to Guide Rifapentine (RPT) Use in the Continuation Phase (continued). Click here for larger image
d
Slide #27 Slide #28
Slide 29: Treatment of Culture-Positive TB: Rifapentine in Continuation Phase. Click here for larger image
d
Slide 30: Algorithm to Guide Treatment of Culture-Negative TB. Click here for larger image
d
Slide #29 Slide #30
Slide 31: Algorithm to Guide the Treatment of Culture-Negative TB (continued). Click here for larger image
d
Slide 32: Treatment of Culture-Negative TB. Click here for larger image
d
Slide #31 Slide #32
Slide 33: Treatment Monitoring (1). Click here for larger image
d
Slide 34: Treatment Monitoring (2). Click here for larger image
d
Slide #33 Slide #34
Slide 35: Treatment Monitoring (3). Click here for larger image
d
Slide 36: Determining Drug Completion (1). Click here for larger image
d
Slide #35 Slide #36
Slide 37: Determining Drug Completion (2). Click here for larger image
d
Slide 38: Management of Initial Phase Treatment Interruptions. Click here for larger image
d
Slide #37 Slide #38
Slide 39: Algorithm for Management of Treatment Interruptions in the Initial Phase. Click here for larger image
d
Slide 40: Management of Continuation Phase Treatment Interruptions. Click here for larger image
d
Slide #39 Slide #40
Slide 41: Management of Continuation Phase Treatment Interruptions. Click here for larger image
d
Slide 42: Algorithm for Management of Continuation Phase Treatment Interruptions. Click here for larger image
d
Slide #41 Slide #42
Slide 43: Common Adverse Reactions to Drug Treatment (1). Click here for larger image
d
Slide 44: Common Adverse Reactions to Drug Treatment (2). Click here for larger image
d
Slide #43 Slide #44
Slide 45: Common Adverse Reactions to Drug Treatment (3). Click here for larger image
d
Slide 46: Drug Interactions. Click here for larger image
d
Slide #45 Slide #46
Slide 47: Relapse (1). Click here for larger image
d
Slide 48: Relapse (2). Click here for larger image
d
Slide #47 Slide #48
Slide 49: Treatment Failure. Click here for larger image
d
Slide 50: Drug Resistance (1). Click here for larger image
d
Slide #49 Slide #50
Slide 51: Drug Resistance (2). Click here for larger image
d
Slide 52: Special Treatment Situations - HIV/AIDS . Click here for larger image
d
Slide #51 Slide #52
Slide 53: Special Treatment Situations (Children and Adolescents)(1). Click here for larger image
d
Slide 54: Special Treatment Situations: Children and Adolescents(2). Click here for larger image
d
Slide #53 Slide #54
Slide 55: Special Treatment Situations: Extrapulmonary TB. Click here for larger image
d
Slide 56: Special Treatment Situations: Pregnancy and Breastfeeding(1). Click here for larger image
d
Slide #55 Slide #56
Slide 57: Special Treatment Situations: Pregnancy and Breastfeeding(2). Click here for larger image
d
Slide 58: Special Treatment Situations: Renal Insufficiency and End-Stage Renal Disease(1). Click here for larger image
d
Slide #57 Slide #58
Slide 59: Special Treatment Situations: Renal Insufficiency and End-Stage Renal Disease(2). Click here for larger image
d
Slide 60: Special Treatment Situations: Hepatic Disease(1). Click here for larger image
d
Slide #59 Slide #60
Slide 61: Special Treatment Situations: Hepatic Disease(2). Click here for larger imaged Slide 62: Continuing Education Credits(1). Click here for larger imaged
Slide #61 Slide #62
Slide 63: Continuing Education Credits(2). Click here for larger imaged Slide 64: Treatment Guidelines Online Availability. Click here for larger imaged
Slide #63 Slide #64
Slide 65: Additional TB Resources. Click here for larger imaged  
Slide #65  

Last Reviewed: 05/18/2008
Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Back to Top of Page


You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format.  Download the Adobe Acrobat™ Reader.

If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available.

Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348
E-mail: tbinfo@cdc.gov


Skip Bottom Nav Home | Site Map | Contact Us
Accessibility | Privacy Policy Notice | FOIA | USA.gov
CDC Home | Search | Health Topics A-Z

Centers for Disease Control & Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to: CDCINFO@cdc.gov